O
Olivia Spleiss
Researcher at Hoffmann-La Roche
Publications - 23
Citations - 2089
Olivia Spleiss is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Vemurafenib & Melanoma. The author has an hindex of 14, co-authored 23 publications receiving 1918 citations.
Papers
More filters
Journal ArticleDOI
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
Fei Su,Amaya Viros,Carla Milagre,Kerstin Trunzer,Gideon Bollag,Olivia Spleiss,Jorge S. Reis-Filho,Xiangju Kong,Richard C. Koya,Keith T. Flaherty,Paul B. Chapman,Min Jung Kim,Robert Hayward,Matthew J. Martin,Hong Yang,Qiongqing Wang,Holly Hilton,Julie S. Hang,Johannes Noe,Maryou B K Lambros,Felipe C. Geyer,Nathalie Dhomen,Ion Niculescu-Duvaz,Alfonso Zambon,Dan Niculescu-Duvaz,Natasha Preece,Lidia Robert,Nicholas Otte,Stephen Mok,Damien Kee,Yan Ma,Chao Zhang,Gaston Habets,Elizabeth A. Burton,Bernice Wong,Hoa Nguyen,Mark M. Kockx,Luc Andries,Brian Lestini,K. B. Nolop,Richard J. Lee,Andrew K. Joe,James L. Troy,Rene Gonzalez,Thomas E. Hutson,Igor Puzanov,Bartosz Chmielowski,Caroline J. Springer,Grant A. McArthur,Jeffrey A. Sosman,Roger S. Lo,Antoni Ribas,Richard Marais +52 more
TL;DR: In this article, the authors performed a molecular analysis to identify oncogenic mutations (HRAS, KRAS, NRAS, CDKN2A, and TP53) in the lesions from patients treated with the BRAF inhibitor vemurafenib.
Journal ArticleDOI
Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
Kerstin Trunzer,Anna C. Pavlick,Lynn M. Schuchter,Rene Gonzalez,Grant A. McArthur,Thomas E. Hutson,Stergios J. Moschos,Keith T. Flaherty,Kevin B. Kim,Jeffrey S. Weber,Peter Hersey,Georgina V. Long,Donald P. Lawrence,Patrick A. Ott,Ravi K. Amaravadi,Karl D. Lewis,Igor Puzanov,Roger S. Lo,Astrid Koehler,Mark M. Kockx,Olivia Spleiss,Annette Schell-Steven,Houston Gilbert,Louise Cockey,Gideon Bollag,Richard J. Lee,Andrew K. Joe,Jeffrey A. Sosman,Antoni Ribas +28 more
TL;DR: Vemurafenib inhibits tumor proliferation and oncogenic BRAF signaling through the MAPK pathway and inhibition downstream of BRAF should help to overcome acquired resistance.
Journal ArticleDOI
Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients.
Jordan Madic,Jordan Madic,Anna Kiialainen,François-Clément Bidard,Fabian Birzele,Guillemette Ramey,Quentin Leroy,Thomas Rio Frio,Isabelle Vaucher,Virginie Raynal,Virginie Bernard,Alban Lermine,Inga Clausen,Nicolas Giroud,Roland Schmucki,Maud Milder,Maud Milder,Carsten Horn,Olivia Spleiss,Olivier Lantz,Olivier Lantz,Marc-Henri Stern,Marc-Henri Stern,Jean-Yves Pierga,Jean-Yves Pierga,Martin Weisser,Ronald Lebofsky +26 more
TL;DR: In this article, the authors used the high prevalence of TP53 mutations in triple negative breast cancer (TNBC) to compare ctDNA and CTC detection rates and prognostic value in metastatic TNBC patients.
Journal ArticleDOI
Association of four DNA polymorphisms with acute rejection after kidney transplantation
Josep M. Grinyó,Yves Vanrenterghem,Bjoern Nashan,Flavio Vincenti,Henrik Ekberg,Klaus Lindpaintner,Michelle Rashford,Clare Nasmyth-Miller,Athina Voulgari,Olivia Spleiss,Matthew Truman,Laurent Essioux +11 more
TL;DR: Variation in genes of immune response and pharmacodynamic/pharmacokinetic relevance may be important in understanding acute rejection after renal transplant.
Journal ArticleDOI
Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact
Federico Goodsaid,Shashi Amur,Jiri Aubrecht,Michael E. Burczynski,Kevin Carl,Jennifer Catalano,Rosane Charlab,Sandra L Close,Catherine Cornu-Artis,Laurent Essioux,Albert J. Fornace,Lois Hinman,Huixiao Hong,Ian Hunt,David Jacobson-Kram,Ansar Jawaid,David Laurie,Lawrence J. Lesko,Heng-Hong Li,Klaus Lindpaintner,James T. Mayne,Peter Morrow,Marisa Papaluca-Amati,Timothy W. Robison,John Roth,Ina Schuppe-Koistinen,Leming Shi,Olivia Spleiss,Weida Tong,Sharada Louis Truter,Jacky Vonderscher,Agnes Westelinck,Li Zhang,Issam Zineh +33 more
TL;DR: A selection of case studies from the first 5 years of the US Food and Drug Administration's voluntary exploratory data submission programme, which also involves collaboration with the European Medicines Agency, are discussed, and general lessons are highlighted.